Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient? by Aneela N. Mian et al.
RESEARCH ARTICLE Open Access
Optimal responses in disease activity
scores to treatment in rheumatoid arthritis:
Is a DAS28 reduction of >1.2 sufficient?
Aneela N. Mian1,2*, Fowzia Ibrahim1,2, David L. Scott1,2, James Galloway1,2 and On behalf of the TITRATE study group
Abstract
Background: The overall benefit of intensive treatment strategies in rheumatoid arthritis (RA) remains uncertain.
We explored how reductions in disability and improvements in quality of life scores are affected by alternative
assessments of reductions in disease activity scores for 28 joints (DAS28) in two trials of intensive treatment
strategies in active RA.
Methods: One trial (CARDERA) studied 467 patients with early active RA receiving 24 months of methotrexate
monotherapy or steroid and disease-modifying anti-rheumatic drug (DMARD) combinations. The other trial (TACIT)
studied 205 patients with established active RA; they received 12 months of treatment with DMARD combinations
or biologic agents. We compared changes in the health assessment questionnaire (HAQ) and Euroqol-5D (EQ5D) at
trial endpoints in European League Against Rheumatism (EULAR) good and moderate EULAR responders in patients
in whom complete endpoint data were available.
Results: In the CARDERA trial 98 patients (26 %) were good EULAR responders and 160 (32 %) were EULAR
moderate responders; comparable data in TACIT were 66 (35 %) and 86 (46 %) patients. The magnitude of change
in the HAQ and EQ5D was greater in both trials in EULAR good responders than in EULAR moderate responders.
HAQ scores had a difference in of –0.49 (95 % CI –0.66, –0.32) in the CARDERA and –0.31 (95 % CI –0.47, –0.13) in
the TACIT trial. With the EQ5D comparable differences were 0.12 (95 % CI 0.04, 0.19) and 0.15 (95 % CI 0.05, 0.25).
Both exceeded minimum clinically important differences in HAQ and EQ5D scores.
Conclusions: We conclude that achieving a good EULAR response with DMARDs and biologic agents in active RA
results in substantially improved mean HAQ and EQ5D scores. Patients who achieve such responses should
continue on treatment. However, continuing such treatment strategies is more challenging when only a moderate
EULAR response is achieved. In these patients evidence of additional clinically important benefits in measures such
as the HAQ should also be sought.
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Background
A key goal in treating rheumatoid arthritis (RA) with
conventional disease-modifying anti-rheumatic drugs
(DMARDs) and biologic agents is reducing inflammatory
synovitis, which reduces disability and maximises quality
of life. Reductions in synovitis with treatment are
assessed using the disease activity score for 28 joints
(DAS28) [1]. The European League Against Rheumatism
(EULAR) classifies good responders as having DAS28
scores of 3.2 or less with reductions in DAS28 of more
than 1.2 [2]. Patients with DAS28 scores over 3.2 who
have reductions in DAS28 scores of more than 1.2 have
moderate responses. Patients with reductions in DAS28
of less than 0.6 are non-responders. The treat-to-target
initiative recommends increasing treatment until patients
achieve remission or low disease activity [3].
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High-cost biologic treatments such as tumour necrosis
factor inhibitors are used within agreed guidelines.
When patients achieve good EULAR responses there is
strong rationale for maintaining treatment. Similarly,
when patients do not respond there is no reason to con-
tinue treatment. However, there is uncertainty in pa-
tients with incomplete responses. The British Society for
Rheumatology (BSR), recommends patients with active
RA, who have not responded to methotrexate and an-
other DMARD, should be considered for biologic ther-
apy [4]. Provided they achieve reductions in DAS28 of
over 1.2 by 6 months they should continue receiving
biologic treatments. This approach was accepted by the
National Institute for Health And Care Excellence
(NICE) in its health technology appraisals of biologic
treatments for RA [5, 6]. Initially NICE recommended
only continuing treatment if DAS28 is reduced by 1.2 or
more [5], though recent guidelines recommend patients
achieve at least a moderate EULAR response for treat-
ment to continue [6].
The impact on disability and quality of life of reducing
disease activity are assessed using the Health Assessment
Questionnaire (HAQ) [7] and EuroQol-5D (EQ5D) [8].
There are doubts about the value both to patients and
the funders of healthcare from maintaining high-cost
treatments if patients only achieve moderate EULAR re-
sponses. We hypothesised that patients with good EULAR
responses have substantially larger improvements in HAQ
and EQ5D scores than patients with moderate EULAR re-
sponses, who do not achieve low disease activity or remis-
sion, and in whom the final DAS28 scores remain over
3.2. We tested our hypothesis in secondary analyses of
two published randomised controlled trials (RCTs). One
trial, cost-effectiveness of treatment strategies using com-
bination of disease modifying anti-rheumatic drugs and
glucocorticoids in early rheumatoid arthritis (CARDERA),
studied intensive DMARD treatment in early RA [9]. The
other trial, tumour necrosis factor inhibitors against com-
bination intensive therapy (TACIT), studied intensive
treatment with DMARDs and biologic agents in estab-
lished RA [10]. In both trials we compared changes in
HAQ and EQ5D scores in patients achieving good
EULAR responses with patients achieving reductions in




We undertook secondary analyses using data from two
completed randomised controlled trials in RA. Details
of the patients and treatments used have been published
[8, 9]. The CARDERA trial randomised 467 patients to
monotherapy or combination therapy with conventional
DMARDs and steroids in early untreated active RA. The
TACIT trial randomised 205 patients to intensive conven-
tional DMARDs or biologic treatment strategies in estab-
lished active RA. In TACIT all patients met the current
NICE criteria for biologic treatments.
Assessments
Both trials used the DAS28 calculated with erythrocyte
sedimentation rate (ESR) to assess disease activity. We
studied patients at the predefined final endpoints of each
trial: 24 months for CARDERA and 12 months for
TACIT. Both trials measured disability using the HAQ
and quality of life using the EQ5D. We applied reported
minimal clinically important differences (MCID) to as-
sess benefits from reducing DAS28 scores. For the HAQ
we used an MCID of 0.22 [11]. For the EQ5D we used
an MCID of 0.07 [12]. We used the DAS28 to assess re-
mission, which was defined by DAS28 < 2.6; this defin-
ition has been widely used [13].
Analyses
We used IBM SPSS statistical software (version 22). De-
scriptive statistics described means, standard error and
confidence intervals. We studied patients with all data
available at the trial endpoints. We divided patients into
EULAR non-responders, moderate responders and good
responders. We compared changes in HAQ and EQ5D
scores between good and moderate EULAR responders
for each trial using the independent samples t test. We
also subdivided moderate and good EULAR responders
by their final DAS28 scores. In addition, we used the
previous NICE criterion for remaining on treatment
(change in DAS28 score >1.2) to categorise patients, rep-
licating EULAR response criteria by dividing patients
into those who also achieved DAS28 low disease activity
scores at the trial endpoint and those who did not. Fi-
nally, we assessed the numbers of patients who achieved
different levels of improvement in HAQ and EuroQol




In the CARDERA trial 121 patients (32 %) were EULAR
non-responders, 160 (42 %) moderate responders and 98
(26 %) good responders. In the TACIT trial 34 patients
(18 %) were EULAR non-responders, 86 (46 %) moder-
ate responders and 66 (35 %) good responders. The trial
designs differed, with all patients in TACIT but not
CARDERA receiving intensive therapy; consequently,
differences in response rates were expected. In both
trials demographic characteristics, clinical variables like
DAS28 scores and components of the DAS28, HAQ and
EQ5D scores were similar across groups. As this
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secondary analysis does not assess treatment effects no
comparative data between groups are presented.
Baseline and endpoint scores
Baseline and final endpoint data for DAS28 and HAQ
and EQ5D scores in both trials for different EULAR re-
sponses are shown in Table 1. In the CARDERA trial
there were no significant differences between baseline
scores in any EULAR responder groups. In the TACIT
trial the good EULAR responders had lower baseline
HAQ scores and higher baseline EQ5D scores.
Differences in disability between EULAR moderate and
good responders
Only patients with either moderate or good EULAR re-
sponses had significant reductions in HAQ scores at the
trial endpoints (Table 2). Moderate responders had reduc-
tions in HAQ scores of 0.39 and 0.33 in the CARDERA
and TACIT trials, respectively. Good responders had re-
ductions of 0.88 and 0.64, respectively. In both trials the
difference between moderate and good responders
exceeded the MCID for HAQ scores (0.22) with differ-
ences in reductions of 0.49 and 0.30, respectively. These
differences were significant (p < 0.01, unpaired t test).
Changes in quality of life
The mean EQ5D scores had a similar pattern. Only
patients with moderate or good EULAR responses had
significant improvements in EQ5D scores at the trial
endpoints (Table 3). Moderate responders had increases
in EQ5D scores of 0.18 and 0.15 in the CARDERA and
TACIT trials, respectively. Good responders had in-
creases of 0.30 in both trials. The difference between
moderate and good responders exceeded the EQ5D
MCID (0.07) in both trials with differences in increases
in EQ5D scores of 0.12 and 0.15, respectively. These dif-
ferences were significant (p < 0.01, unpaired t test).
Alternative assessments of response
Similar analyses based on patients achieving reductions
in DAS28 > 1.2, subdivided by whether or not they also
achieved low DAS28 at the trial endpoints, were similar
in relation to both HAQ and EQ5D scores. Patients who
did not achieve low disease activity scores had only
modest improvements in both scores (detailed results
not shown).
Additional benefits of achieving remission
Another analysis subdivided patients achieving good
EULAR responses into those who were also in remission
and those who were not at the trial endpoints. In the
CARDERA trial 70/98 patients (71 %) with good re-
sponses were in remission and 28/98 (29 %) were not.
There were non-significant benefits for both HAQ
scores and EQ5D scores with remission; mean differ-
ences between groups were –0.29 (95 % CI –0.61, 0.02)
for HAQ scores and 0.11 (–0.02, 0.24) for EQ5D scores.
In the TACIT trial 41/66 patients (62 %) with good re-
sponses were in remission and 25/66 (38 %) were not.
There were also non-significant benefits for both HAQ
scores and EQ5D scores with remission. The mean dif-
ferences between the groups were –0.13 (–0.41, 0.14) for
HAQ and 0.08 (–0.07, 0.24) for EQ5D.
Categories of HAQ and EQ5D change with EULAR
responses
In the CARDERA trial 63 % of patients with moderate
EULAR responses had improvements in HAQ exceeding
the MCID (0.22) compared with 79 % of patients with
good EULAR responses. In the TACIT trial 57 % of pa-
tients with moderate EULAR responses had improvements
in HAQ exceeding the MCID compared with 80 % of
patients with good EULAR responses. On more detailed
analysis (Fig. 1) there was a wide range in HAQ score im-
provements in both trials in moderate and good EULAR
responders; more patients with large improvements in
Table 1 Baseline and endpoint assessments in completers in the TACIT and CARDERA trials (mean scores (95 % confidence intervals))
EULAR Response Number DAS28 HAQ EQ5D
Initial Endpoint Initial Endpoint Initial Endpoint
CARDERA trial
None 121 5.45 (5.22, 5.68) 5.67 (5.45, 5.89) 1.43 (1.30, 1.56 1.53 (1.39, 1.67) 0.46 (0.40, 0.51) 0.48 (0.43, 0.53)
Moderate 160 6.08 (5.89, 6.27) 4.21 (4.07, 4.35) 1.70 (1.60, 1.80) 1.31 (1.20, 1.42) 0.42 (0.37, 0.46) 0.60 (0.56, 0.63)
Good 98 5.57 (5.33, 5.80) 2.17 (2.04, 2.30) 1.47 (1.35, 1.60) 0.60 (0.48, 0.72) 0.47 (0.42, 0.52) 0.77 (0.73, 0.80)
TACIT trial
None 34 6.40 (6.08, 6.71) 6.34 (6.06, 6.63) 2.15 (2.00, 2.29) 2.11 (1.94, 2.28) 0.22 (0.11, 0.33) 0.23 (0.13, 0.34)
Moderate 86 6.30 (6.11, 6.49) 4.23 (4.07, 4.38) 1.91 (1.78, 2.04) 1.58 (1.42, 1.73) 0.41 (0.35, 0.47) 0.56 (0.51, 0.61)
Good 66 6.13 (5.96, 6.30) 2.29 (2.14, 2.44) 1.64 (1.47, 1.81) 1.00 (0.81, 1.19) 0.40 (0.32, 0.47) 0.69 (0.64, 0.75)
TACIT tumour necrosis factor inhibitors against combination intensive therapy, CARDERA cost-effectiveness of treatment strategies using combination of disease
modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis, EULAR European League Against Rheumatism, DAS28 twenty-eight joint disease
activity score, HAQ Health Assessment Questionnaire, EQ5D Euroqol-5D
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HAQ scores exceeding 1.0 had good EULAR responses,
particularly in the early RA trial (CARDERA). In this trial
41 % of patients with good EULAR responses had im-
provements in HAQ over 1.0.
Changes were similar with the EQ5D scores. In the
CARDERA trial 59 % of patients with moderate EULAR
responses had improvements in EQ5D scores exceeding
the MCID (0.07) compared with 80 % of patients with
good EULAR responses. In the TACIT trial 59 % of pa-
tients with moderate EULAR responses had improve-
ments in EQ5D scores exceeding the MCID compared
with 79 % of patients with good EULAR responses. On
more detailed analysis (Fig. 2) there was a wide range in
improvement in the EQ5D scores in both trials in mod-
erate and good EULAR responders; more patients with
good EULAR responses had large improvements in
EQ5D scores. The benefits from achieving good EULAR
responses were less marked with improvements in
EQ5D scores.
Discussion
Our secondary analyses of two large English RCTs in
early and established active RA shows that patients with
good EULAR responses have larger clinically meaningful
improvements in disability and quality of life than pa-
tients with moderate EULAR responses. These findings
support the concept of treat-to-target. They indicate that
achieving low disease activity or remission states should
be the treatment goal. The benefits of good EULAR re-
sponses are seen in both early and established RA. The
findings were similar if we used the earlier NICE criter-
ion of an improvement in DAS28 of more than 1.2.
The reliance of current NICE guidance on changes in
DAS28 of more than 1.2 has been criticised by Jerram et
al [14], who point out that this threshold was not used
in clinical trials. This concern is ameliorated by the new
NICE guidance. Judging patients’ responses to DMARDs
and biologic therapy is challenging. EULAR response
criteria were designed for use in individual patients and
trials. The other major composite response criteria, the
American College of Rheumatology (ACR) criteria, are
only intended for trials. These two validated response
criteria have been compared in several studies [15, 16];
they measure similar changes. However, their use in rou-
tine clinical practice and relating their findings to pa-
tients’ perceived responses requires more research. Gulfe
et al. showed that when response criteria are used at the
individual patient level the results are difficult to inter-
pret [17]. Ward et al. [18] found patients’ perceptions of
improvement may differ from conventional assessments
like ACR20 responses, and that thresholds of minimal
clinically important improvement may be larger than
previously thought, including the need for a DAS28 im-
provement of at least 1.2 [19]. Among patients receiving
treatment for active RA, three months may be the opti-
mal time point to increase the intensity of treatment
[20]. However, when assessing response to biologic ther-
apy, real-world evidence suggests a six-month time point
is needed to optimise patients’ responses [21].
Low disease activity optimises key patient-related out-
comes like HAQ and EQ5D scores [22–24]. Our own
findings mirror these previous reports. Remission is one
potentially important outcome, although only a minority
of our patients achieved this. Interestingly some other
trials in early RA, such as the FIN-RACo trial [25], re-
ported higher remission rates; the reasons for this hetero-
geneity are uncertain. When patients achieve sustained
remission, they have less long-term work disability [26].
Some patients with moderate EULAR responses in our tri-
als had good reductions in disability and improvements in
quality of life. However, many did not and the best man-
agement of such patients is uncertain. Continuing to pre-
scribe high-cost biologic therapy for patients with modest
improvements in disease activity and little or no reduction
in disability seems questionable. It may be preferable to
continue biologic treatments in patients with moderate
EULAR responses who have also had clinically meaningful
reductions in disability.
Our report has several strengths. The two trials were
large, there was reasonable patient retention on treatment,
Table 2 Changes in disability (HAQ scores) by EULAR response mean scores (95 % confidence intervals)
None Moderate Good Difference moderate and good
CARDERA 0.10 (–0.01, 0.21) –0.39 (–0.48, –0.30) –0.88 (–1.02, –0.73) –0.49 (–0.66, –0.32)
TACIT –0.04 (–0.15, 0.08) –0.33 (-0.44, -0.22) –0.64 (–0.77, –0.51) –0.30 (–0.47, –0.13)
EULAR European League Against Rheumatism, CARDERA cost-effectiveness of treatment strategies using combination of disease-modifying anti-rheumatic drugs
and glucocorticoids in early rheumatoid arthritis, TACIT tumour necrosis factor inhibitors against combination intensive therapy
Table 3 Changes in health-related quality of life (EQ5D scores) by EULAR response mean scores (95 % confidence intervals)
None Moderate Good Difference moderate and good
CARDERA 0.02 (–0.03, 0.07) 0.18 (0.14, 0.23) 0.30 (0.24, 0.35) 0.12 (0.04, 0.19)
TACIT 0.00 (–0.13, 0.14) 0.15 (0.08, 0.21) 0.30 (0.22, 0.37) 0.15 (0.05, 0.25)
EQ5D EuroQol-5D, EULAR European League Against Rheumatism, CARDERA cost-effectiveness of treatment strategies using combination of disease-modifying
anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis, TACIT tumour necrosis factor inhibitors against combination intensive therapy
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and they were based across many English specialist
centres with a broad geographic spread. We found
similar effects in trials of early and established RA.
Our findings are therefore likely to be generalisable in
guiding clinical practice decisions.
Our analyses also have limitations. First, we only con-
sidered differences at the trial endpoints. Different ef-
fects would have been seen by evaluating all time points.
Second, choosing specific cutoff points, such as DAS28
of 3.2 or less may have over done similarly well. Third,
some of the treatments used, particularly ciclosporin,
which was used in the CARDERA trial, are not commonly
prescribed in routine practice. Fourth, we combined the
effects of a range of different treatments, and the relation-
ship between disease activity and HAQ and EQ5D scores
may be different across drug classes. Finally, our inference
that patients who do not achieve low DAS28 scores with
one treatment strategy may do better with another could
be incorrect; some patients may achieve poor outcomes
with all treatment strategies.
Conclusions
Achieving good EULAR responses to treatment with
DMARDs and biologic agents leads to substantial im-
provements in HAQ and EQ5D scores. Patients who
achieve such responses should continue on treatment.
Fig. 1 Changes in Health Assessment Questionnaire (HAQ) scores in four categories in moderate and good European League Against Rheumatism
(EULAR) responders in both the cost-effectiveness of treatment strategies using combination of disease-modifying anti-rheumatic drugs
and glucocorticoids in early rheumatoid arthritis (CARDERA), and tumour necrosis factor inhibitors against combination intensive therapy
(TACIT) trials
Fig. 2 Changes in EuroQol-5D (EQ5D) scores in four categories in moderate and good European League Against Rheumatism (EULAR) responders
in both the cost-effectiveness of treatment strategies using combination of disease-modifying anti-rheumatic drugs and glucocorticoids in early
rheumatoid arthritis (CARDERA), and tumour necrosis factor inhibitors against combination intensive therapy (TACIT) trials
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However, continuing patients on intensive treatment
regimens, particularly using high-cost biologic agents, is
more challenging if they only achieve moderate EULAR
responses. Evidence of additional clinically important
benefits in measures such as the HAQ should also be
sought to justify continuing treatment in these patients.
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